Trial record 1 of 1 for:    NCT00874029
Previous Study | Return to List | Next Study

Laparoscopic Radiofrequency Ablation of Symptomatic Uterine Fibroids (Halt Lap RFA)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Halt Medical, Inc Identifier:
First received: April 1, 2009
Last updated: March 20, 2013
Last verified: March 2013

The purpose of this study is to demonstrate the safety and effectiveness of radiofrequency ablation (RFA) using the Halt System for the treatment of patients with symptomatic uterine fibroids.

Condition Intervention
Uterine Fibroids
Uterine Myomas
Device: Halt Procedure

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Halt System for Laparoscopic Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation

Further study details as provided by Halt Medical, Inc:

Primary Outcome Measures:
  • Menstrual bleeding at 12 months compared to pre-procedure (baseline) [ Time Frame: 12 months from Baseline ] [ Designated as safety issue: No ]
  • Incidence of device and procedure-related adverse events within 12 months post-procedure [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Surgical re-Intervention for menorrhagia at 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Uterine and fibroid volume at 12 months post-procedure compared to pre-procedure (baseline) as measured with contrast-enhanced MRI (magnetic resonance imaging) [ Time Frame: 12 month from Baseline ] [ Designated as safety issue: No ]
  • Fibroid Symptom severity and quality of life at 12 months post-procedure as compared to pre-procedure (baseline) using the Uterine Fibroid Symptom and Health Related Quality of Life (UFS-QoL) assessment tool. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • General health outcome at 12 months post-procedure as compared to pre-procedure using the EQ-5D (a standardized instrument for use as a measure of health outcome) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Overall subject treatment outcome and satisfaction using the Overall Treatment Evaluation (OTE) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: March 2009
Estimated Study Completion Date: February 2014
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Halt Procedure
In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
Device: Halt Procedure
The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
Other Names:
  • Halt
  • Halt2000
  • The Halt System
  • The Halt 2000 System

Detailed Description:

In this single-arm study, subjects who have symptomatic uterine fibroids will have laparoscopic surgery in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.


Ages Eligible for Study:   25 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Are premenopausal and ≥ 25 years old
  • Have symptomatic uterine fibroids
  • Have a uterine gestational size ≤14 weeks as determined by pelvic exam
  • Have ≤ 6 (six) treatable fibroids in whom no single fibroid exceeds 7 cm in any diameter as measured by ultrasound or magnetic resonance imaging (MRI). Only Fibroids greater than 1cm in diameter should be treated in this study
  • Have a total uterine fibroid volume that does not exceed 300cc on ultrasound or contrast-enhanced MRI evaluation
  • Have clinical menorrhagia as indicated by menstrual blood loss of ≥160 mL to 500 ml during one baseline cycle or two baseline cycles within three months prior to treatment
  • Have a history of at least 3 months of menorrhagia within the last six months
  • Desire uterine preservation
  • Do not desire current or future childbearing
  • Have a normal coagulation profile (INR, Platelets, PT, and PTT)
  • Have had a normal Pap smear within the past 12 months
  • Are practicing non-hormonal or stable hormonal contraception
  • If the woman is not currently taking any hormonal contraceptives, has been off all hormonal contraceptives for a minimum of three months prior to study enrollment, and agrees to continue without change in regimen through the 12 months of follow-up OR
  • If the woman is currently taking hormonal contraceptives, has taken hormonal contraceptives for a minimum of three months prior to study enrollment, and agrees to continue without change in regimen through 12 months of follow up.**

    **Note: Hormonal contraceptive use must be terminated 30 days prior to treatment but should be resumed post-operatively within 60 days post treatment as instructed by the Investigator.

  • Are willing and able to comply with all study tests, procedures, and assessment tools
  • Are willing and able to return for all required follow up visits following study enrollment
  • Must pass a pre-operative health exam (ASA I-III)
  • Are capable of providing informed consent

Exclusion Criteria:

  • Have contraindications for laparoscopic surgery and/or general anesthesia. (Contraindications include anemia, defined as a hemoglobin level under 10 or hematocrit level less than 30.)
  • Have had prior pelvic surgery (with the exception of C-section, tubal ligation, or diagnostic laparoscopy), or are known to have significant intra-abdominal adhesions (defined as adhesions that would require extensive dissection to mobilize and view all surfaces of the uterus)
  • Have previously undergone endometrial ablation, uterine artery embolization, or uterine artery ligation, or any other uterine-preserving technique for reduction of menstrual bleeding (with the exception of hysteroscopic myomectomy > 1 year ago)
  • Patients requiring elective concomitant procedures
  • Have contraindications for magnetic resonance imaging (MRI)
  • Desire current or future childbearing
  • Are pregnant or lactating
  • Have taken any GnRh agonist within three months prior to the screening procedures
  • Have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed one month prior to treatment
  • Have dysfunctional uterine bleeding or bleeding between periods
  • Have chronic pelvic pain not due to uterine fibroids
  • Have known or suspected endometriosis
  • Have known or suspected adenomyosis based on Ultrasound or MRI findings
  • Have active or history of pelvic inflammatory disease
  • Have a history of or evidence of gynecologic malignancy or pre-malignancy within the past five years
  • Have had pelvic radiation
  • Have a non-uterine pelvic mass
  • Have a cervical myoma
  • Have one or more pedunculated subserosal fibroids or "type zero" (completely intracavitary) submucous fibroids
  • Are peri-menopausal (defined as women 40 years of age or older with FSH level of ≥ 25 IU) or menopausal
  • Are unable to give informed consent
  • In the medical judgment of the investigator should not participate in the study
  Contacts and Locations
Please refer to this study by its identifier: NCT00874029

United States, Arizona
Women's Health Research
Phoenix, Arizona, United States, 85015
United States, California
USC Medical Center
Los Angeles, California, United States, 90033
Pasadena Premier Women's Health
Pasadena, California, United States, 91145
Reproductive Science Center
San Ramon, California, United States, 94583
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48034
United States, Missouri
St. Luke's Hospital
Chesterfield, Missouri, United States, 63017
United States, Nevada
Athena Gynecology Medical Group
Reno, Nevada, United States, 89509
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10461
United States, Pennsylvania
Magee-Women's Hospital
Pittsburgh, Pennsylvania, United States, 15213
Hospital Universitario Esperanza
Guatemala City, Guatemala, 01010
Hospital Universitario Dr. Jose Eleuterio Gonzalez de la Universidad Autonoma de Nuevo Leon. Facultad de Medicina
Monterrey, Nuevo Leon, Mexico, 64460
Sponsors and Collaborators
Halt Medical, Inc
Principal Investigator: Mary Hinckley, MD Reproductive Science Center
Principal Investigator: Micah Harris, MD Women's Health Research
Principal Investigator: Erika Banks, MD Montefiore Medical Center
Principal Investigator: Karen R Abbott, MD Athena Gynecology Medical Group
Principal Investigator: Jay Berman, MD Wayne State University
Principal Investigator: Jose G Garza Leal, MD Hospital Universitario Dr. Jose Eleuterio Gonzalez
Principal Investigator: David Levine, MD St. Johns' Mercy Medical Center
Principal Investigator: Rodolfo Robles Pemueller, MD Universidad Francisco Marroquin
Principal Investigator: Jennifer Israel, MD University of Southern California
Principal Investigator: Richard S Guido, MD Magee-Women's Hospital
Principal Investigator: James Macer, MD Pasadena Premier Women's Health
  More Information

No publications provided by Halt Medical, Inc

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Halt Medical, Inc Identifier: NCT00874029     History of Changes
Other Study ID Numbers: CP-00-0004
Study First Received: April 1, 2009
Last Updated: March 20, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Halt Medical, Inc:
Uterine Fibroids

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases processed this record on April 17, 2014